Grail, Inc. (NASDAQ:GRAL) Short Interest Update

Grail, Inc. (NASDAQ:GRAL) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 3,780,000 shares, an increase of 7.1% from the October 31st total of 3,530,000 shares. Based on an average trading volume of 743,000 shares, the short-interest ratio is presently 5.1 days. Currently, 14.4% of the company’s stock are short sold.

Insider Buying and Selling at Grail

In other news, CEO Robert P. Ragusa sold 123,454 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the transaction, the chief executive officer now owns 612,661 shares in the company, valued at $8,589,507.22. This represents a 16.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Chun R. Ding bought 7,629 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was bought at an average price of $13.52 per share, with a total value of $103,144.08. Following the completion of the purchase, the insider now directly owns 3,503,655 shares in the company, valued at $47,369,415.60. This represents a 0.22 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 58,829 shares of company stock worth $757,298 over the last three months.

Grail Trading Up 3.4 %

GRAL stock opened at $19.36 on Wednesday. Grail has a 12 month low of $12.33 and a 12 month high of $23.36. The company has a fifty day simple moving average of $14.60.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Morgan Stanley initiated coverage on shares of Grail in a report on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 price objective on the stock. Wolfe Research initiated coverage on Grail in a research note on Friday, November 15th. They set a “peer perform” rating on the stock. Finally, Guggenheim started coverage on Grail in a research note on Thursday, October 17th. They issued a “neutral” rating for the company.

About Grail

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.